{
  "trial_id": "NCT06926920",
  "title": "A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer",
  "condition": "Triple Negative Breast Cancer",
  "participant_count": 100,
  "bias_type": "biased",
  "age_distribution": {
    "mean": 48.43,
    "std": 14.776622951763565,
    "min": 19,
    "max": 80
  },
  "gender_distribution": {
    "male": 0.25238256359108546,
    "female": 0.7476174364089145
  },
  "ethnicity_distribution": {
    "white": 0.7,
    "black": 0.15,
    "asian": 0.1,
    "hispanic": 0.04,
    "other": 0.01
  },
  "sample_size": 100,
  "eligibility_score": 0.821849900518714
}